Breakthrough Designation for Celldex's (CLDX) Rintega Points to Stronger FDA Support as Cancer Vaccine in GBM - Roth Capital
Tweet Send to a Friend
Roth Capital affirms Celldex Therapeutics (Nasdaq: CLDX) at Buy/Focus Pick with a $43 price target following news that the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
